Can children of the Sputnik V vaccine recipients become symptomatic?
Sputnik V is one of the most promising vaccines, utilizing an Adenovirus vector to cause immunity against SARS-CoV-2. Concerns existed against Adenovirus infection with this vaccine, although seemed to be a rare event. In this study, we observed that 15/18 (83%) of the children of the Sputnik V reci...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2021-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_5335a982dc154ae7835463d6570d14ec | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Esmaeil Mehraeen |e author |
| 700 | 1 | 0 | |a SeyedAhmad SeyedAlinaghi |e author |
| 700 | 1 | 0 | |a Amirali Karimi |e author |
| 245 | 0 | 0 | |a Can children of the Sputnik V vaccine recipients become symptomatic? |
| 260 | |b Taylor & Francis Group, |c 2021-10-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2021.1933689 | ||
| 520 | |a Sputnik V is one of the most promising vaccines, utilizing an Adenovirus vector to cause immunity against SARS-CoV-2. Concerns existed against Adenovirus infection with this vaccine, although seemed to be a rare event. In this study, we observed that 15/18 (83%) of the children of the Sputnik V recipients became symptomatic and developed transient fever and chills for 1-2 days starting after 2-5 days following the vaccination of their parents that can be related to an Adenovirus infection. To our knowledge, this is the first study reporting such symptoms in the children of Sputnik V recipients, and the results should be validated by larger studies. | ||
| 546 | |a EN | ||
| 690 | |a adverse events | ||
| 690 | |a covid-19 | ||
| 690 | |a sars-cov-2 | ||
| 690 | |a sputnik v | ||
| 690 | |a vaccine | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 17, Iss 10, Pp 3500-3501 (2021) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2021.1933689 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/5335a982dc154ae7835463d6570d14ec |z Connect to this object online. |